Search

Your search keyword '"Whitaker, Hayley"' showing total 383 results

Search Constraints

Start Over You searched for: Author "Whitaker, Hayley" Remove constraint Author: "Whitaker, Hayley"
383 results on '"Whitaker, Hayley"'

Search Results

1. Combining tissue biomarkers with mpMRI to diagnose clinically significant prostate cancer. Analysis of 21 biomarkers in the PICTURE study

2. ssVERDICT: Self-Supervised VERDICT-MRI for Enhanced Prostate Tumour Characterisation

4. Prostate MR image quality of apparent diffusion coefficient maps versus fractional intracellular volume maps from VERDICT MRI using the PI-QUAL score and a dedicated Likert scale for artefacts

5. Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth

7. ssVERDICT: Self‐supervised VERDICT‐MRI for enhanced prostate tumor characterization.

8. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets

9. The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates

14. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue

17. DESNT: A Poor Prognosis Category of Human Prostate Cancer

18. Regional Histopathology and Prostate MRI Positivity: A Secondary Analysis of the PROMIS Trial

19. ST6GAL1‐mediated aberrant sialylation promotes prostate cancer progression

20. Use of artificial intelligence in the detection of primary prostate cancer in multiparametric MRI with its clinical outcomes: a protocol for a systematic review and meta-analysis

22. Author Correction: Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer

23. A critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologists

25. Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer

29. Data from Engrailed-2 (EN2): A Tumor Specific Urinary Biomarker for the Early Diagnosis of Prostate Cancer

31. Supplementary Data from Engrailed-2 (EN2): A Tumor Specific Urinary Biomarker for the Early Diagnosis of Prostate Cancer

32. Data from Prognostic and Therapeutic Impact of Argininosuccinate Synthetase 1 Control in Bladder Cancer as Monitored Longitudinally by PET Imaging

33. Supplementary Figure 3 from Prognostic and Therapeutic Impact of Argininosuccinate Synthetase 1 Control in Bladder Cancer as Monitored Longitudinally by PET Imaging

34. Supplementary Tables 1 - 4 from Prognostic and Therapeutic Impact of Argininosuccinate Synthetase 1 Control in Bladder Cancer as Monitored Longitudinally by PET Imaging

35. Supplementary Figure 2 from Prognostic and Therapeutic Impact of Argininosuccinate Synthetase 1 Control in Bladder Cancer as Monitored Longitudinally by PET Imaging

36. Supplementary Figure 4 from Prognostic and Therapeutic Impact of Argininosuccinate Synthetase 1 Control in Bladder Cancer as Monitored Longitudinally by PET Imaging

37. Supplementary Figure 1 from Prognostic and Therapeutic Impact of Argininosuccinate Synthetase 1 Control in Bladder Cancer as Monitored Longitudinally by PET Imaging

38. Supplementary Figure Legend from Prognostic and Therapeutic Impact of Argininosuccinate Synthetase 1 Control in Bladder Cancer as Monitored Longitudinally by PET Imaging

39. Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging

40. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns

41. Combined burden and functional impact tests for cancer driver discovery using DriverPower

42. Integrative pathway enrichment analysis of multivariate omics data

43. Pathway and network analysis of more than 2500 whole cancer genomes

44. Divergent mutational processes distinguish hypoxic and normoxic tumours

45. Genomic footprints of activated telomere maintenance mechanisms in cancer

46. Avoiding Unnecessary Biopsy after Multiparametric Prostate MRI with VERDICT Analysis: The INNOVATE Study

48. Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth

49. Comparison of Multiparametric Magnetic Resonance Imaging with Prostate-Specific Membrane Antigen Positron-Emission Tomography Imaging in Primary Prostate Cancer Diagnosis: A Systematic Review and Meta-Analysis

50. Differentiating False Positive Lesions from Clinically Significant Cancer and Normal Prostate Tissue Using VERDICT MRI and Other Diffusion Models

Catalog

Books, media, physical & digital resources